NEW DELHI, March 10, 2026 /PRNewswire/ -- The demand for advanced Neurodegenerative Disease Devices is being significantly driven by the growing burden of progressive neurological disorders across developed healthcare economies. Rapid demographic aging in countries such as Japan, Germany, and France is contributing to a steady rise in patients diagnosed with Parkinson's disease, Alzheimer's disease, epilepsy, essential tremor, and other chronic degenerative conditions. As life expectancy increases, the requirement for long-term therapeutic intervention, functional support, and continuous neurological monitoring is expanding, thereby strengthening the adoption of specialized device-based solutions.
Across the treatment continuum, neurostimulation devices, diagnostic and imaging systems, interventional neurology technologies, surgical navigation and support platforms, cerebrospinal fluid (CSF) management devices, monitoring and wearable solutions, as well as assistive and rehabilitation systems are playing an increasingly critical role in disease management. Advancements such as programmable stimulation settings, MRI-compatible implants, real-time data analytics, miniaturized device architecture, and remote monitoring capabilities are enhancing therapeutic precision and long-term patient outcomes. Collectively, these innovations are reinforcing the clinical value of neurodegenerative disease devices and sustaining consistent product demand across developed healthcare systems.
Vyansa Intelligence has published strategic research reports on the Neurodegenerative Disease Devices Market across major countries, providing insights into competitive dynamics, regulatory frameworks, and future growth opportunities.
Japan Neurodegenerative Disease Devices Market: The Neurodegenerative Disease Devices Market in Japan is estimated at approximately USD 900 million in 2025 and is projected to reach nearly USD 1.25 billion by 2032, registering a CAGR of around 4.8% during 2026–2032. This significant growth is primarily driven by Japan's rapidly aging population, which is contributing to higher diagnosis rates of Parkinson's disease and Alzheimer's disease, the latter accounting for nearly 40% of total device demand.
Browse full report on Japan Neurodegenerative Disease Devices Market at: https://www.vyansaintelligence.com/industry-report/japan-neurodegenerative-disease-devices-market-size
In response to rising diagnostic requirements, diagnostic and imaging devices command approximately 40% of the market, reflecting a strong emphasis on early detection and continuous neurological monitoring. The competitive landscape remains moderately consolidated, with more than 10 active companies operating in the country. However, the top five players collectively account for nearly 70% of total market share, including Stryker, Nihon Kohden Corporation, Smith & Nephew, Medtronic, and LivaNova. Moreover, robust hospital infrastructure, supportive reimbursement policies, and steady technological adoption continue to reinforce sustained device demand nationwide.
Germany Neurodegenerative Disease Devices Market: The Neurodegenerative Disease Devices Market in Germany is estimated at approximately USD 1.74 billion in 2025 and is projected to reach nearly USD 2.63 billion by 2032. Along with this, the market is expanding at a CAGR of around 6.08% during 2026–2032, supported by increasing geriatric demographics and rising adoption of advanced neuromodulation therapies.
Based on device type, neurostimulation devices account for nearly 50% of total market share, reflecting strong procedural volumes in deep brain stimulation and related implantable technologies. Additionally, Parkinson's disease represents approximately 40% of total device demand, driven by growing clinical intervention rates. The market remains moderately consolidated, with more than 10 active participants, while the top five companies collectively command around 80% share. Key players include Stryker, Integra LifeSciences, Nevro Corp., Medtronic, and Boston Scientific. Strong reimbursement structures, advanced hospital infrastructure, and regulatory compliance under European standards continue to support steady device penetration across Germany.
Browse full report on Japan Neurodegenerative Disease Devices Market at: https://www.vyansaintelligence.com/industry-report/germany-neurodegenerative-disease-devices-market-outlook
France Neurodegenerative Disease Devices Market: The Neurodegenerative Disease Devices Market in France is valued at approximately USD 1.5 billion in 2025 and is expected to reach nearly USD 2.5 billion by 2032, registering a CAGR of around 7.57% during the forecast period. Demand growth is supported by increasing diagnosis of age-related neurological disorders and the expansion of device-based therapeutic interventions.
Neurostimulation devices hold nearly 40% of the total market share, indicating rising adoption of implantable stimulation systems across tertiary care centers. Alzheimer's disease accounts for approximately 45% of overall device demand, reflecting the country's aging demographic profile. More than 10 companies operate within the market, with the top five players collectively accounting for around 60% share. Leading companies include Johnson & Johnson, Smith & Nephew, Philips Healthcare, Boston Scientific, and Medtronic. Furthermore, structured reimbursement pathways and ongoing innovation initiatives continue to strengthen long-term device adoption in France.
Browse full report on France Neurodegenerative Disease Devices Market at: https://www.vyansaintelligence.com/industry-report/france-neurodegenerative-disease-devices-market-outlook
Future of Neurodegenerative Disease Devices
Over the coming years, neurodegenerative disease devices are expected to be shaped by advancements in precision neuromodulation, minimally invasive implantation techniques, and AI-integrated diagnostics. Next-generation deep brain stimulation and neurostimulation systems are likely to incorporate closed-loop feedback mechanisms, rechargeable platforms, and improved battery longevity to enhance therapeutic outcomes.
Increasing integration of digital health technologies, remote programming, and real-time patient monitoring will further strengthen long-term disease management. In addition, miniaturization of implantable devices and development of MRI-compatible systems are anticipated to improve safety and clinical flexibility. As aging populations expand globally, sustained demand for innovative therapeutic and diagnostic neuro devices is expected to drive steady technological evolution.
Neurodegenerative Disease Devices Market Segmentation:
About Vyansa Intelligence
Vyansa Intelligence is a globally recognized market research and advisory firm delivering comprehensive industry intelligence across emerging and established markets. The company provides in-depth syndicated research reports that offer detailed analysis of market dynamics, growth outlook, technology advancements, regulatory developments, and competitive landscapes influencing global industries. Backed by robust research methodologies, proprietary analytical frameworks, and validated primary and secondary data sources, Vyansa Intelligence enables enterprises, investors, and policymakers to make informed strategic decisions with confidence. Its forward-looking insights help stakeholders identify high-growth opportunities, assess competitive positioning, manage risks, and develop sustainable long-term business strategies across dynamic and evolving market environments.
For any inquiries, please contact:
Office: Office No.110, H-159, Sector 63, Noida, Uttar Pradesh - 201301, India
Contact No: +91 7065555003
Email: sales@vyansaintelligence.com
Website: vyansaintelligence.com
Logo - https://mma.prnewswire.com/media/2929228/5853189/Vyansa_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/neurodegenerative-disease-devices-market-to-witness-steady-growth-through-2032-driven-by-advanced-neuromodulation-says-vyansa-intelligence-302708607.html
Zalando hat 2025 kräftig zugelegt und seine eigenen Ziele am oberen Ende der Spannen erreicht. Der Umsatz des im DAX notierten Online-Modehändlers stieg um 16,8 Prozent auf 12,35 Milliarden Euro und lag damit leicht über den Markterwartungen. Das Bruttowarenvolumen (GMV) kletterte um 14,7 Prozent auf 17,56 Milliarden Euro. Rückenwind bekam das Geschäft vor allem durch die Übernahme des Konkurrenten About You sowie den verstärkten Einsatz Künstlicher Intelligenz in Vertrieb und Plattformsteuerung.
Operativ verbesserte sich Zalando ebenfalls: Das bereinigte Ergebnis vor Zinsen und Steuern (EBIT) erhöhte sich auf 591 Millionen Euro nach 511 Millionen Euro im Vorjahr, die Marge blieb mit 4,8 Prozent stabil und leicht über den Analystenprognosen. Unter dem Strich sank der Gewinn jedoch auf 213 Millionen Euro von zuvor 251 Millionen Euro und verfehlte damit die Erwartungen. Für das laufende Jahr stellt das Management ein weiteres Wachstum von 12 bis 17 Prozent bei GMV und Umsatz in Aussicht; das bereinigte EBIT soll auf 660 bis 740 Millionen Euro steigen. Die mittelfristigen Ziele bis 2028 – jährliche Zuwächse von 8 bis 13 Prozent bei Umsatz und GMV sowie eine EBIT-Marge von 6 bis 8 Prozent – wurden bestätigt, die angepeilten jährlichen Synergien aus der About-You-Übernahme von 100 Millionen Euro sollen bereits 2028 und damit ein Jahr früher erreicht sein.
An der Börse sorgte vor allem die Kapitalmarktpolitik für Auftrieb. Der Konzern kündigte ein Aktienrückkaufprogramm von bis zu 300 Millionen Euro an, das bis Ende Juli laufen soll. Die Aktie legte im Tagesverlauf zweistellig zu und notierte zeitweise rund elf Prozent höher bei 22,35 Euro. Damit reagierte der Markt positiv auf die Kombination aus besser als erwarteten operativen Kennzahlen, bestätigtem Wachstumskurs und der Ankündigung, überschüssiges Kapital an die Anteilseigner zurückzuführen – obwohl die Zalando-Papiere seit Jahresbeginn deutlich im Minus liegen und in den vergangenen zwölf Monaten rund ein Drittel an Wert verloren haben. Analysten hoben neben dem Rückkauf insbesondere die Rolle von KI und das Konzept des sogenannten Agentic Commerce als nächste Entwicklungsstufe des Onlinehandels hervor.
Überschattet werden die guten Zahlen von strukturellen Einschnitten im Logistiknetz. Im Zuge der Integration von About You will Zalando vier Logistikzentren in Europa schließen, darunter den Standort Erfurt mit rund 2.700 Beschäftigten. Co-Chef David Schröter sprach von einer der schwersten, zugleich aber notwendigen Entscheidungen, um die Kapazitäten an den künftigen Wachstumsbedarf anzupassen. Das Unternehmen verhandelt nach eigenen Angaben mit dem Betriebsrat über einen Sozialplan, bietet Versetzungen an andere Standorte an und arbeitet mit der örtlichen Arbeitsagentur zusammen. Weitere Maßnahmen über die bereits angekündigten Schließungen hinaus soll es dem Management zufolge nicht geben; aus der Thüringer Landespolitik kommt dennoch Kritik an der Entscheidung.
,regionOfInterest=(955,281)&hash=27c131b7533e2d4916860cc04ae4112762ad11c6c6490fc505e779e190a65bcd)